Skip to main content
Top
Published in: Immunologic Research 2-3/2013

01-07-2013 | Etio Pathogenesis of Autoimmunity

Tracing environmental markers of autoimmunity: introducing the infectome

Authors: Dimitrios P. Bogdanos, Daniel S. Smyk, Pietro Invernizzi, Eirini I. Rigopoulou, Miri Blank, Lazaros Sakkas, Shideh Pouria, Yehuda Shoenfeld

Published in: Immunologic Research | Issue 2-3/2013

Login to get access

Abstract

We recently introduced the concept of the infectome as a means of studying all infectious factors which contribute to the development of autoimmune disease. It forms the infectious part of the exposome, which collates all environmental factors contributing to the development of disease and studies the sum total of burden which leads to the loss of adaptive mechanisms in the body. These studies complement genome-wide association studies, which establish the genetic predisposition to disease. The infectome is a component which spans the whole life and may begin at the earliest stages right up to the time when the first symptoms manifest, and may thus contribute to the understanding of the pathogenesis of autoimmunity at the prodromal/asymptomatic stages. We provide practical examples and research tools as to how we can investigate disease-specific infectomes, using laboratory approaches employed from projects studying the “immunome” and “microbiome”. It is envisioned that an understanding of the infectome and the environmental factors that affect it will allow for earlier patient-specific intervention by clinicians, through the possible treatment of infectious agents as well as other compounding factors, and hence slowing or preventing disease development.
Literature
6.
go back to reference Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223–43.PubMedCrossRef Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223–43.PubMedCrossRef
9.
go back to reference Brickman CM, Shoenfeld Y. The mosaic of autoimmunity. Scand J Clin Lab Invest Suppl. 2001;235:3–15.PubMed Brickman CM, Shoenfeld Y. The mosaic of autoimmunity. Scand J Clin Lab Invest Suppl. 2001;235:3–15.PubMed
10.
go back to reference Rahamim-Cohen D, Shoenfeld Y. The mosaic of autoimmunity. a classical case of inhalation of a polyclonal activating factor in a genetically and hormonally susceptible patient leading to multiple autoimmune diseases. Isr Med Assoc J. 2001;3(5):381–2.PubMed Rahamim-Cohen D, Shoenfeld Y. The mosaic of autoimmunity. a classical case of inhalation of a polyclonal activating factor in a genetically and hormonally susceptible patient leading to multiple autoimmune diseases. Isr Med Assoc J. 2001;3(5):381–2.PubMed
11.
go back to reference Shepshelovich D, Shoenfeld Y. Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. Lupus. 2006;15(3):183–90.PubMedCrossRef Shepshelovich D, Shoenfeld Y. Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. Lupus. 2006;15(3):183–90.PubMedCrossRef
12.
go back to reference Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases–2008. Isr Med Assoc J. 2008;10(1):13–9.PubMed Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases–2008. Isr Med Assoc J. 2008;10(1):13–9.PubMed
13.
go back to reference Shoenfeld Y, Gilburd B, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, et al. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases–2008. Isr Med Assoc J. 2008;10(1):3–7.PubMed Shoenfeld Y, Gilburd B, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, et al. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases–2008. Isr Med Assoc J. 2008;10(1):3–7.PubMed
14.
go back to reference Asherson RA, Gunter K, Daya D, Shoenfeld Y. Multiple autoimmune diseases in a young woman: tuberculosis and splenectomy as possible triggering factors? Another example of the “mosaic” of autoimmunity. J Rheumatol. 2008;35(6):1224–6.PubMed Asherson RA, Gunter K, Daya D, Shoenfeld Y. Multiple autoimmune diseases in a young woman: tuberculosis and splenectomy as possible triggering factors? Another example of the “mosaic” of autoimmunity. J Rheumatol. 2008;35(6):1224–6.PubMed
15.
go back to reference de Carvalho JF, Pereira RM, Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors. Front Biosci (Elite Ed). 2009;1:501–9. de Carvalho JF, Pereira RM, Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors. Front Biosci (Elite Ed). 2009;1:501–9.
17.
go back to reference Mavropoulos A, Orfanidou T, Liaskos C, Smyk DS, Billinis C, Blank M, et al. p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: lessons to learn from ANCA vasculitis and pemphigus vulgaris. Autoimmun Rev. 2012;. doi:10.1016/j.autrev.2012.10.019.PubMed Mavropoulos A, Orfanidou T, Liaskos C, Smyk DS, Billinis C, Blank M, et al. p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: lessons to learn from ANCA vasculitis and pemphigus vulgaris. Autoimmun Rev. 2012;. doi:10.​1016/​j.​autrev.​2012.​10.​019.PubMed
22.
go back to reference Selmi C, Leung PS, Sherr DH, Diaz M, Nyland JF, Monestier M, et al. Mechanisms of environmental influence on human autoimmunity: a national institute of environmental health sciences expert panel workshop. J Autoimmun. 2012;39(4):272–84. doi:10.1016/j.jaut.2012.05.PubMedCrossRef Selmi C, Leung PS, Sherr DH, Diaz M, Nyland JF, Monestier M, et al. Mechanisms of environmental influence on human autoimmunity: a national institute of environmental health sciences expert panel workshop. J Autoimmun. 2012;39(4):272–84. doi:10.​1016/​j.​jaut.​2012.​05.PubMedCrossRef
23.
go back to reference Bogdanos DP, Smith H, Ma Y, Baum H, Mieli-Vergani G, Vergani D. A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol. 2005;12(3):217–24.PubMedCrossRef Bogdanos DP, Smith H, Ma Y, Baum H, Mieli-Vergani G, Vergani D. A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol. 2005;12(3):217–24.PubMedCrossRef
24.
go back to reference Smyk DS, Rigopoulou EI, Muratori L, Burroughs AK, Bogdanos DP. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Ann Hepatol. 2012;11(1):7–14.PubMed Smyk DS, Rigopoulou EI, Muratori L, Burroughs AK, Bogdanos DP. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Ann Hepatol. 2012;11(1):7–14.PubMed
25.
go back to reference Miller FW, Alfredsson L, Costenbader KH, Kamen DL, Nelson LM, Norris JM, et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a national institute of environmental health sciences expert panel workshop. J Autoimmun. 2012;39(4):259–71. doi:10.1016/j.jaut.2012.05.002.PubMedCrossRef Miller FW, Alfredsson L, Costenbader KH, Kamen DL, Nelson LM, Norris JM, et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a national institute of environmental health sciences expert panel workshop. J Autoimmun. 2012;39(4):259–71. doi:10.​1016/​j.​jaut.​2012.​05.​002.PubMedCrossRef
26.
28.
go back to reference Arlt VM, Schwerdtle T. UKEMS/Dutch EMS-sponsored workshop on biomarkers of exposure and oxidative DNA damage & 7th GUM-32P-postlabelling workshop, University of Munster, Munster, Germany, 28-29 March 2011. Mutagenesis. 2011. doi: 10.1093/mutage/ger036. Arlt VM, Schwerdtle T. UKEMS/Dutch EMS-sponsored workshop on biomarkers of exposure and oxidative DNA damage & 7th GUM-32P-postlabelling workshop, University of Munster, Munster, Germany, 28-29 March 2011. Mutagenesis. 2011. doi: 10.​1093/​mutage/​ger036.
36.
go back to reference McCulloch J, Zhang YW, Dawson M, Harkiss GD, Peterhans E, Vogt HR, et al. Glycosylation of IgG during potentially arthritogenic lentiviral infections. Rheumatol Int. 1995;14(6):243–8.PubMedCrossRef McCulloch J, Zhang YW, Dawson M, Harkiss GD, Peterhans E, Vogt HR, et al. Glycosylation of IgG during potentially arthritogenic lentiviral infections. Rheumatol Int. 1995;14(6):243–8.PubMedCrossRef
37.
go back to reference Polacco BJ, Purvine SO, Zink EM, Lavoie SP, Lipton MS, Summers AO, et al. Discovering mercury protein modifications in whole proteomes using natural isotope distributions observed in liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics. 2011;. doi:10.1074/mcp.M110.004853.PubMed Polacco BJ, Purvine SO, Zink EM, Lavoie SP, Lipton MS, Summers AO, et al. Discovering mercury protein modifications in whole proteomes using natural isotope distributions observed in liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics. 2011;. doi:10.​1074/​mcp.​M110.​004853.PubMed
38.
go back to reference McLaren Howard J. The detection of DNA adducts (risk factors for DNA damage). A method for genomic DNA, the results and some effects of nutritional intervention. J Nutr Environ Med. 2002;12:19–31.CrossRef McLaren Howard J. The detection of DNA adducts (risk factors for DNA damage). A method for genomic DNA, the results and some effects of nutritional intervention. J Nutr Environ Med. 2002;12:19–31.CrossRef
40.
go back to reference Karges W, Hammond-McKibben D, Cheung RK, Visconti M, Shibuya N, Kemp D, et al. Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow’s milk-based IDDM prevention trial. Diabetes. 1997;46(4):557–64.PubMedCrossRef Karges W, Hammond-McKibben D, Cheung RK, Visconti M, Shibuya N, Kemp D, et al. Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow’s milk-based IDDM prevention trial. Diabetes. 1997;46(4):557–64.PubMedCrossRef
41.
go back to reference Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Immunol. 2004;172(1):661–8.PubMed Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Immunol. 2004;172(1):661–8.PubMed
48.
go back to reference Otsuki T, Hayashi H, Nishimura Y, Hyodo F, Maeda M, Kumagai N, et al. Dysregulation of autoimmunity caused by silica exposure and alteration of Fas-mediated apoptosis in T lymphocytes derived from silicosis patients. Int J Immunopathol Pharmacol. 2011;24(1 Suppl):11S–6S.PubMed Otsuki T, Hayashi H, Nishimura Y, Hyodo F, Maeda M, Kumagai N, et al. Dysregulation of autoimmunity caused by silica exposure and alteration of Fas-mediated apoptosis in T lymphocytes derived from silicosis patients. Int J Immunopathol Pharmacol. 2011;24(1 Suppl):11S–6S.PubMed
49.
go back to reference Cooper GS, Wither J, Bernatsky S, Claudio JO, Clarke A, Rioux JD, et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology. 2010;49(11):2172–80. doi:10.1093/rheumatology/keq214.PubMedCrossRef Cooper GS, Wither J, Bernatsky S, Claudio JO, Clarke A, Rioux JD, et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology. 2010;49(11):2172–80. doi:10.​1093/​rheumatology/​keq214.PubMedCrossRef
50.
go back to reference Finckh A, Cooper GS, Chibnik LB, Costenbader KH, Watts J, Pankey H, et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum. 2006;54(11):3648–54. doi:10.1002/art.22210.PubMedCrossRef Finckh A, Cooper GS, Chibnik LB, Costenbader KH, Watts J, Pankey H, et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum. 2006;54(11):3648–54. doi:10.​1002/​art.​22210.PubMedCrossRef
51.
go back to reference Parks CG, Cooper GS. Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus. 2006;15(11):728–36.PubMedCrossRef Parks CG, Cooper GS. Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus. 2006;15(11):728–36.PubMedCrossRef
52.
go back to reference Griffin JM, Gilbert KM, Lamps LW, Pumford NR. CD4(+) T-cell activation and induction of autoimmune hepatitis following trichloroethylene treatment in MRL +/+ mice. Toxicol Sci. 2000;57(2):345–52.PubMedCrossRef Griffin JM, Gilbert KM, Lamps LW, Pumford NR. CD4(+) T-cell activation and induction of autoimmune hepatitis following trichloroethylene treatment in MRL +/+ mice. Toxicol Sci. 2000;57(2):345–52.PubMedCrossRef
55.
go back to reference Parks CG, Walitt BT, Pettinger M, Chen JC, de Roos AJ, Hunt J, et al. Insecticide use and risk of rheumatoid arthritis and systemic lupus erythematosus in the women’s health initiative observational study. Arthritis Care Res. 2011;63(2):184–94. doi:10.1002/acr.20335.CrossRef Parks CG, Walitt BT, Pettinger M, Chen JC, de Roos AJ, Hunt J, et al. Insecticide use and risk of rheumatoid arthritis and systemic lupus erythematosus in the women’s health initiative observational study. Arthritis Care Res. 2011;63(2):184–94. doi:10.​1002/​acr.​20335.CrossRef
59.
go back to reference Sobel ES, Gianini J, Butfiloski EJ, Croker BP, Schiffenbauer J, Roberts SM. Acceleration of autoimmunity by organochlorine pesticides in (NZB x NZW)F1 mice. Environ Health Perspect. 2005;113(3):323–8.PubMedCrossRef Sobel ES, Gianini J, Butfiloski EJ, Croker BP, Schiffenbauer J, Roberts SM. Acceleration of autoimmunity by organochlorine pesticides in (NZB x NZW)F1 mice. Environ Health Perspect. 2005;113(3):323–8.PubMedCrossRef
60.
go back to reference Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect. 1999;107(Suppl 5):743–8.PubMedCrossRef Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect. 1999;107(Suppl 5):743–8.PubMedCrossRef
61.
go back to reference Artukovic M, Ikic M, Kustelega J, Artukovic IN, Kaliterna DM. Influence of UV radiation on immunological system and occurrence of autoimmune diseases. Coll Antropol. 2010;34(Suppl 2):175–8.PubMed Artukovic M, Ikic M, Kustelega J, Artukovic IN, Kaliterna DM. Influence of UV radiation on immunological system and occurrence of autoimmune diseases. Coll Antropol. 2010;34(Suppl 2):175–8.PubMed
62.
66.
go back to reference Pujol M, Duran-Suarez JR, Martin Vega C, Sanchez C, Tovar JL, Valles M. Autoimmune thrombocytopenia in three patients treated with captopril. Vox Sang. 1989;57(3):218.PubMedCrossRef Pujol M, Duran-Suarez JR, Martin Vega C, Sanchez C, Tovar JL, Valles M. Autoimmune thrombocytopenia in three patients treated with captopril. Vox Sang. 1989;57(3):218.PubMedCrossRef
67.
go back to reference Gharavi AE, Sammaritano LR, Wen J, Miyawaki N, Morse JH, Zarrabi MH, et al. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid. J Rheumatol. 1994;21(1):94–9.PubMed Gharavi AE, Sammaritano LR, Wen J, Miyawaki N, Morse JH, Zarrabi MH, et al. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid. J Rheumatol. 1994;21(1):94–9.PubMed
68.
go back to reference Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol. 1988;27(4):272–5.PubMedCrossRef Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol. 1988;27(4):272–5.PubMedCrossRef
69.
go back to reference Stein PB, Inwood MJ. Hemolytic anemia associated with chlorpromazine therapy. Can J Psychiatry. 1980;25(8):659–61.PubMed Stein PB, Inwood MJ. Hemolytic anemia associated with chlorpromazine therapy. Can J Psychiatry. 1980;25(8):659–61.PubMed
70.
go back to reference Hadnagy C. Letter: coombs-positive haemolytic anaemia provoked by chlorpromazine. Lancet. 1976;1(7956):423.PubMedCrossRef Hadnagy C. Letter: coombs-positive haemolytic anaemia provoked by chlorpromazine. Lancet. 1976;1(7956):423.PubMedCrossRef
71.
go back to reference Berglund S, Gottfries CG, Gottfries I, Stormby K. Chlorpromazine-induced antinuclear factors. Act Med Scand. 1970;187(1–2):67–74. Berglund S, Gottfries CG, Gottfries I, Stormby K. Chlorpromazine-induced antinuclear factors. Act Med Scand. 1970;187(1–2):67–74.
72.
go back to reference Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755–74.PubMedCrossRef Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755–74.PubMedCrossRef
73.
go back to reference Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994;20(1):61–86.PubMed Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994;20(1):61–86.PubMed
78.
go back to reference Berlin T, Zandman-Goddard G, Blank M, Matthias T, Pfeiffer S, Weis I, et al. Autoantibodies in nonautoimmune individuals during infections. Ann N Y Acad Sci. 2007;1108:584–93.PubMedCrossRef Berlin T, Zandman-Goddard G, Blank M, Matthias T, Pfeiffer S, Weis I, et al. Autoantibodies in nonautoimmune individuals during infections. Ann N Y Acad Sci. 2007;1108:584–93.PubMedCrossRef
79.
go back to reference Saad R, Rizkallah MR, Aziz RK. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 2012;4(1):16. doi:10.1186/1757-4749-4-16.PubMed Saad R, Rizkallah MR, Aziz RK. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 2012;4(1):16. doi:10.​1186/​1757-4749-4-16.PubMed
82.
85.
go back to reference Toubi E, Shoenfeld Y. Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality? Lupus. 2005;14(9):665–9.PubMedCrossRef Toubi E, Shoenfeld Y. Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality? Lupus. 2005;14(9):665–9.PubMedCrossRef
89.
go back to reference Guilherme L, Oshiro SE, Fae KC, Cunha-Neto E, Renesto G, Goldberg AC, et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun. 2001;69(9):5345–51.PubMedCrossRef Guilherme L, Oshiro SE, Fae KC, Cunha-Neto E, Renesto G, Goldberg AC, et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun. 2001;69(9):5345–51.PubMedCrossRef
90.
go back to reference Amedei A, Bergman MP, Appelmelk BJ, Azzurri A, Benagiano M, Tamburini C, et al. Molecular mimicry between Helicobacter pylori antigens and H + , K + –adenosine triphosphatase in human gastric autoimmunity. J Exp Med. 2003;198(8):1147–56. doi:10.1084/jem.20030530.PubMedCrossRef Amedei A, Bergman MP, Appelmelk BJ, Azzurri A, Benagiano M, Tamburini C, et al. Molecular mimicry between Helicobacter pylori antigens and H + , K + –adenosine triphosphatase in human gastric autoimmunity. J Exp Med. 2003;198(8):1147–56. doi:10.​1084/​jem.​20030530.PubMedCrossRef
91.
go back to reference Cunha-Neto E, Coelho V, Guilherme L, Fiorelli A, Stolf N, Kalil J. Autoimmunity in Chagas’ disease. identification of cardiac myosin-b13 trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas’ cardiomyopathy patient. J Clin Invest. 1996;98(8):1709–12. doi:10.1172/JCI118969.PubMedCrossRef Cunha-Neto E, Coelho V, Guilherme L, Fiorelli A, Stolf N, Kalil J. Autoimmunity in Chagas’ disease. identification of cardiac myosin-b13 trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas’ cardiomyopathy patient. J Clin Invest. 1996;98(8):1709–12. doi:10.​1172/​JCI118969.PubMedCrossRef
92.
go back to reference da Rocha Sobrinho HM, Jarach R, da Silva NA, Shio MT, Jancar S, Timenetsky J. Mycoplasmal lipid-associated membrane proteins and Mycoplasma arthritidis mitogen recognition by serum antibodies from patients with rheumatoid arthritis. Rheumatol Int. 2011;31(7):951–7. doi:10.1007/s00296-010-1612-1.PubMedCrossRef da Rocha Sobrinho HM, Jarach R, da Silva NA, Shio MT, Jancar S, Timenetsky J. Mycoplasmal lipid-associated membrane proteins and Mycoplasma arthritidis mitogen recognition by serum antibodies from patients with rheumatoid arthritis. Rheumatol Int. 2011;31(7):951–7. doi:10.​1007/​s00296-010-1612-1.PubMedCrossRef
96.
go back to reference Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33. doi:10.1056/NEJMoa021933.PubMedCrossRef Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33. doi:10.​1056/​NEJMoa021933.PubMedCrossRef
97.
go back to reference Harley JB, Harley IT, Guthridge JM, James JA. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus. 2006;15(11):768–77.PubMedCrossRef Harley JB, Harley IT, Guthridge JM, James JA. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus. 2006;15(11):768–77.PubMedCrossRef
98.
go back to reference Harley JB, James JA. Epstein-barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis. 2006;64(1–2):45–50.PubMed Harley JB, James JA. Epstein-barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis. 2006;64(1–2):45–50.PubMed
99.
go back to reference Navarra SV, Ishimori MI, Uy EA, Hamijoyo L, Sama J, James JA, et al. Studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first-degree relatives. Lupus. 2011;20(5):537–43. doi:10.1177/0961203310385164.PubMedCrossRef Navarra SV, Ishimori MI, Uy EA, Hamijoyo L, Sama J, James JA, et al. Studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first-degree relatives. Lupus. 2011;20(5):537–43. doi:10.​1177/​0961203310385164​.PubMedCrossRef
101.
go back to reference Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? a preliminary report. Ann N Y Acad Sci. 2007;1108:567–77.PubMedCrossRef Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? a preliminary report. Ann N Y Acad Sci. 2007;1108:567–77.PubMedCrossRef
102.
go back to reference Bengtsson A, Widell A, Elmstahl S, Sturfelt G. No serological indications that systemic lupus erythematosus is linked with exposure to human parvovirus B19. Ann Rheum Dis. 2000;59(1):64–6.PubMedCrossRef Bengtsson A, Widell A, Elmstahl S, Sturfelt G. No serological indications that systemic lupus erythematosus is linked with exposure to human parvovirus B19. Ann Rheum Dis. 2000;59(1):64–6.PubMedCrossRef
103.
go back to reference Hemauer A, Beckenlehner K, Wolf H, Lang B, Modrow S. Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. J Clin Virol. 1999;14(1):73–7.PubMedCrossRef Hemauer A, Beckenlehner K, Wolf H, Lang B, Modrow S. Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. J Clin Virol. 1999;14(1):73–7.PubMedCrossRef
110.
go back to reference Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain. 2000;123(Pt 5):968–74.PubMedCrossRef Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain. 2000;123(Pt 5):968–74.PubMedCrossRef
111.
go back to reference Kurtzke JF, Delasnerie-Laupretre N, Wallin MT. Multiple sclerosis in North African migrants to France. Acta Neurol Scand. 1998;98(5):302–9.PubMedCrossRef Kurtzke JF, Delasnerie-Laupretre N, Wallin MT. Multiple sclerosis in North African migrants to France. Acta Neurol Scand. 1998;98(5):302–9.PubMedCrossRef
115.
116.
go back to reference Sadovnick AD, Ebers GC, Dyment DA, Risch NJ. Evidence for genetic basis of multiple sclerosis the Canadian collaborative study group. Lancet. 1996;347(9017):1728–30.PubMedCrossRef Sadovnick AD, Ebers GC, Dyment DA, Risch NJ. Evidence for genetic basis of multiple sclerosis the Canadian collaborative study group. Lancet. 1996;347(9017):1728–30.PubMedCrossRef
117.
go back to reference Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006;15(18):2813–24. doi:10.1093/hmg/ddl223.PubMedCrossRef Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006;15(18):2813–24. doi:10.​1093/​hmg/​ddl223.PubMedCrossRef
118.
126.
go back to reference Amital H, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepany T, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010;69(6):1155–7. doi:10.1136/ard.2009.120329.PubMedCrossRef Amital H, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepany T, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010;69(6):1155–7. doi:10.​1136/​ard.​2009.​120329.PubMedCrossRef
127.
go back to reference Toubi E, Shoenfeld Y. The role of vitamin D in regulating immune responses. Isr Med Assoc J. 2010;12(3):174–5.PubMed Toubi E, Shoenfeld Y. The role of vitamin D in regulating immune responses. Isr Med Assoc J. 2010;12(3):174–5.PubMed
128.
129.
go back to reference Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011;70(1):145–50. doi:10.1136/ard.2010.134817.PubMedCrossRef Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011;70(1):145–50. doi:10.​1136/​ard.​2010.​134817.PubMedCrossRef
130.
go back to reference Oren Y, Shapira Y, Agmon-Levin N, Kivity S, Zafrir Y, Altman A, et al. Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J. 2010;12(12):751–6.PubMed Oren Y, Shapira Y, Agmon-Levin N, Kivity S, Zafrir Y, Altman A, et al. Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J. 2010;12(12):751–6.PubMed
132.
138.
go back to reference Hedstrom AK, Sundqvist E, Baarnhielm M, Nordin N, Hillert J, Kockum I, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain. 2011;134(Pt 3):653–64. doi:10.1093/brain/awq371.PubMedCrossRef Hedstrom AK, Sundqvist E, Baarnhielm M, Nordin N, Hillert J, Kockum I, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain. 2011;134(Pt 3):653–64. doi:10.​1093/​brain/​awq371.PubMedCrossRef
139.
go back to reference Stejskal V, Hudecek R, Stejskal J, Sterzl I. Diagnosis and treatment of metal-induced side-effects. Neuro Endocrinol Lett. 2006;27(Suppl 1):7–16.PubMed Stejskal V, Hudecek R, Stejskal J, Sterzl I. Diagnosis and treatment of metal-induced side-effects. Neuro Endocrinol Lett. 2006;27(Suppl 1):7–16.PubMed
142.
go back to reference Kim JS, Lee KS, Park JH, Kim MY, Shin WS. Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells from multiple sclerosis patients. Eur Neurol. 2000;43(3):170–3.PubMedCrossRef Kim JS, Lee KS, Park JH, Kim MY, Shin WS. Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells from multiple sclerosis patients. Eur Neurol. 2000;43(3):170–3.PubMedCrossRef
144.
go back to reference Albright AV, Lavi E, Black JB, Goldberg S, O’Connor MJ, Gonzalez-Scarano F. The effect of human herpesvirus-6 (HHV-6) on cultured human neural cells: oligodendrocytes and microglia. J Neurovirol. 1998;4(5):486–94.PubMedCrossRef Albright AV, Lavi E, Black JB, Goldberg S, O’Connor MJ, Gonzalez-Scarano F. The effect of human herpesvirus-6 (HHV-6) on cultured human neural cells: oligodendrocytes and microglia. J Neurovirol. 1998;4(5):486–94.PubMedCrossRef
145.
go back to reference Chan PK, Ng HK, Cheng AF. Detection of human herpesviruses 6 and 7 genomic sequences in brain tumours. J Clin Path. 1999;52(8):620–3.PubMedCrossRef Chan PK, Ng HK, Cheng AF. Detection of human herpesviruses 6 and 7 genomic sequences in brain tumours. J Clin Path. 1999;52(8):620–3.PubMedCrossRef
146.
go back to reference Mirandola P, Stefan A, Brambilla E, Campadelli-Fiume G, Grimaldi LM. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology. 1999;53(6):1367–8.PubMedCrossRef Mirandola P, Stefan A, Brambilla E, Campadelli-Fiume G, Grimaldi LM. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology. 1999;53(6):1367–8.PubMedCrossRef
150.
go back to reference Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42(5):1194–202. doi:10.1002/hep.20907.PubMedCrossRef Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42(5):1194–202. doi:10.​1002/​hep.​20907.PubMedCrossRef
154.
go back to reference Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis. 2005;25(3):265–80. doi:10.1055/s-2005-916319.PubMedCrossRef Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis. 2005;25(3):265–80. doi:10.​1055/​s-2005-916319.PubMedCrossRef
159.
go back to reference Konikoff F, Pecht M, Theodor E, Shoenfeld Y. Primary biliary cirrhosis: lymphocyte subsets and function in a time frame. Hepatology. 1989;10(4):525–6.PubMedCrossRef Konikoff F, Pecht M, Theodor E, Shoenfeld Y. Primary biliary cirrhosis: lymphocyte subsets and function in a time frame. Hepatology. 1989;10(4):525–6.PubMedCrossRef
160.
go back to reference Schlesinger M, Benbassat C, Shoenfeld Y. Complement profile in primary biliary cirrhosis. Immunol Res. 1992;11(2):98–103.PubMedCrossRef Schlesinger M, Benbassat C, Shoenfeld Y. Complement profile in primary biliary cirrhosis. Immunol Res. 1992;11(2):98–103.PubMedCrossRef
161.
go back to reference Shoenfeld Y. Primary biliary cirrhosis and autoimmune rheumatic diseases: prediction and prevention. Isr J Med Sci. 1992;28(2):113–6.PubMed Shoenfeld Y. Primary biliary cirrhosis and autoimmune rheumatic diseases: prediction and prevention. Isr J Med Sci. 1992;28(2):113–6.PubMed
162.
go back to reference Weiss P, Shoenfeld Y. Primary biliary cirrhosis is a multisystem disorder. Ann Med Interne (Paris). 1991;142(4):283–7. Weiss P, Shoenfeld Y. Primary biliary cirrhosis is a multisystem disorder. Ann Med Interne (Paris). 1991;142(4):283–7.
163.
go back to reference Weiss P, Shoenfeld Y. Primary biliary cirrhosis: increasing problem, approaching solution. Isr J Med Sci. 1992;28(10):726–8.PubMed Weiss P, Shoenfeld Y. Primary biliary cirrhosis: increasing problem, approaching solution. Isr J Med Sci. 1992;28(10):726–8.PubMed
164.
go back to reference Benbassat C, Schlesinger M, Shoenfeld Y. The complement system and primary biliary cirrhosis. J Clin Lab Immunol. 1992;38(2):51–61.PubMed Benbassat C, Schlesinger M, Shoenfeld Y. The complement system and primary biliary cirrhosis. J Clin Lab Immunol. 1992;38(2):51–61.PubMed
165.
go back to reference Rotman P, Levy Y, Shoenfeld Y. Primary biliary cirrhosis–association or overlap with other autoimmune diseases. Isr J Med Sci. 1997;33(12):823–5.PubMed Rotman P, Levy Y, Shoenfeld Y. Primary biliary cirrhosis–association or overlap with other autoimmune diseases. Isr J Med Sci. 1997;33(12):823–5.PubMed
166.
go back to reference Shapira S, Bar-Dayan Y, Gershwin ME, Shoenfeld Y. Is it possible to predict and prevent primary biliary cirrhosis? Harefuah. 1999;137(1–2):39–41.PubMed Shapira S, Bar-Dayan Y, Gershwin ME, Shoenfeld Y. Is it possible to predict and prevent primary biliary cirrhosis? Harefuah. 1999;137(1–2):39–41.PubMed
168.
169.
go back to reference Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis. 2003;7(4):759–77.PubMedCrossRef Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis. 2003;7(4):759–77.PubMedCrossRef
173.
go back to reference Gershwin ME, Mackay IR. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology. 1991;100(3):822–33.PubMed Gershwin ME, Mackay IR. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology. 1991;100(3):822–33.PubMed
174.
go back to reference Mackay IR, Whittingham S, Fida S, Myers M, Ikuno N, Gershwin ME, et al. The peculiar autoimmunity of primary biliary cirrhosis. Immunol Rev. 2000;174:226–37.PubMedCrossRef Mackay IR, Whittingham S, Fida S, Myers M, Ikuno N, Gershwin ME, et al. The peculiar autoimmunity of primary biliary cirrhosis. Immunol Rev. 2000;174:226–37.PubMedCrossRef
175.
go back to reference Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med. 1995;181(5):1835–45.PubMedCrossRef Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med. 1995;181(5):1835–45.PubMedCrossRef
176.
go back to reference Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushima T, Gershwin ME, et al. Mimicry peptides of human PDC-E2 163–176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology. 2000;31(6):1212–6. doi:10.1053/jhep.2000.8090.PubMedCrossRef Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushima T, Gershwin ME, et al. Mimicry peptides of human PDC-E2 163–176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology. 2000;31(6):1212–6. doi:10.​1053/​jhep.​2000.​8090.PubMedCrossRef
177.
go back to reference Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest. 1998;102(10):1831–40. doi:10.1172/JCI4213.PubMedCrossRef Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest. 1998;102(10):1831–40. doi:10.​1172/​JCI4213.PubMedCrossRef
181.
go back to reference Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol. 2008;14(21):3374–87.PubMedCrossRef Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol. 2008;14(21):3374–87.PubMedCrossRef
184.
go back to reference Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35(4):436–42. doi:10.1016/j.jaut.2010.09.005.PubMedCrossRef Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35(4):436–42. doi:10.​1016/​j.​jaut.​2010.​09.​005.PubMedCrossRef
185.
go back to reference Ma Y, Thomas MG, Okamoto M, Bogdanos DP, Nagl S, Kerkar N, et al. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J Immunol. 2002;169(1):277–85.PubMed Ma Y, Thomas MG, Okamoto M, Bogdanos DP, Nagl S, Kerkar N, et al. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J Immunol. 2002;169(1):277–85.PubMed
186.
187.
go back to reference Wen L, Ma Y, Bogdanos DP, Wong FS, Demaine A, Mieli-Vergani G, et al. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Molec Med. 2001;1(3):379–89.CrossRef Wen L, Ma Y, Bogdanos DP, Wong FS, Demaine A, Mieli-Vergani G, et al. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Molec Med. 2001;1(3):379–89.CrossRef
189.
go back to reference Rigopoulou EI, Bogdanos DP, Liaskos C, Koutsoumpas A, Baum H, Vergani D, et al. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta. 2007;380(1–2):118–21. doi:10.1016/j.cca.2007.01.023.PubMedCrossRef Rigopoulou EI, Bogdanos DP, Liaskos C, Koutsoumpas A, Baum H, Vergani D, et al. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta. 2007;380(1–2):118–21. doi:10.​1016/​j.​cca.​2007.​01.​023.PubMedCrossRef
190.
go back to reference Gilburd B, Ziporen L, Zharhary D, Blank M, Zurgil N, Scheinberg MA, et al. Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy. J Clin Immunol. 1994;14(1):14–9.PubMedCrossRef Gilburd B, Ziporen L, Zharhary D, Blank M, Zurgil N, Scheinberg MA, et al. Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy. J Clin Immunol. 1994;14(1):14–9.PubMedCrossRef
191.
go back to reference Konikoff F, Isenberg DA, Barrison I, Theodor E, Shoenfeld Y. Antinuclear autoantibodies in chronic liver diseases. Hepatogastroenterology. 1989;36(5):341–5.PubMed Konikoff F, Isenberg DA, Barrison I, Theodor E, Shoenfeld Y. Antinuclear autoantibodies in chronic liver diseases. Hepatogastroenterology. 1989;36(5):341–5.PubMed
192.
go back to reference Konikoff F, Isenberg DA, Kooperman O, Kennedy RC, Rauch J, Theodor E, et al. Common lupus anti-DNA antibody idiotypes in chronic liver diseases. Clin Immunol Immunopathol. 1987;43(2):265–72.PubMedCrossRef Konikoff F, Isenberg DA, Kooperman O, Kennedy RC, Rauch J, Theodor E, et al. Common lupus anti-DNA antibody idiotypes in chronic liver diseases. Clin Immunol Immunopathol. 1987;43(2):265–72.PubMedCrossRef
193.
go back to reference Konikoff F, Shoenfeld Y, Isenberg DA, Barrison I, Sobe T, Theodor E, et al. Anti-Rnp antibodies in chronic liver diseases. Clin Exp Rheumatol. 1987;5(4):359–61.PubMed Konikoff F, Shoenfeld Y, Isenberg DA, Barrison I, Sobe T, Theodor E, et al. Anti-Rnp antibodies in chronic liver diseases. Clin Exp Rheumatol. 1987;5(4):359–61.PubMed
194.
go back to reference Krause I, Hacham S, Gilburd B, Damianovitch M, Blank M, Shoenfeld Y. Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. Clin Immunol Immunopathol. 1995;77(3):229–35.PubMedCrossRef Krause I, Hacham S, Gilburd B, Damianovitch M, Blank M, Shoenfeld Y. Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. Clin Immunol Immunopathol. 1995;77(3):229–35.PubMedCrossRef
195.
go back to reference Lorber M, Kra-Oz Z, Guilbrud B, Shoenfeld Y. Natural (antiphospholipid-PDH,-DNA) autoantibodies and their physiologic serum inhibitors. Isr J Med Sci. 1995;31(1):31–5.PubMed Lorber M, Kra-Oz Z, Guilbrud B, Shoenfeld Y. Natural (antiphospholipid-PDH,-DNA) autoantibodies and their physiologic serum inhibitors. Isr J Med Sci. 1995;31(1):31–5.PubMed
196.
go back to reference Maran R, Dueymes M, Adler Y, Shoenfeld Y, Youinou P. Isotypic distribution of anti-pyruvate dehydrogenase antibodies in patients with primary biliary cirrhosis and their family members. J Clin Immunol. 1994;14(5):323–6.PubMedCrossRef Maran R, Dueymes M, Adler Y, Shoenfeld Y, Youinou P. Isotypic distribution of anti-pyruvate dehydrogenase antibodies in patients with primary biliary cirrhosis and their family members. J Clin Immunol. 1994;14(5):323–6.PubMedCrossRef
197.
go back to reference Shoenfeld Y, Beresovski A, Zharhary D, Tomer Y, Swissa M, Sela E, et al. Natural autoantibodies in sera of patients with Gaucher’s disease. J Clin Immunol. 1995;15(6):363–72.PubMedCrossRef Shoenfeld Y, Beresovski A, Zharhary D, Tomer Y, Swissa M, Sela E, et al. Natural autoantibodies in sera of patients with Gaucher’s disease. J Clin Immunol. 1995;15(6):363–72.PubMedCrossRef
198.
go back to reference Zurgil N, Bakimer R, Kaplan M, Youinou P, Shoenfeld Y. Anti-pyruvate dehydrogenase autoantibodies in primary biliary cirrhosis. J Clin Immunol. 1991;11(5):239–45.PubMedCrossRef Zurgil N, Bakimer R, Kaplan M, Youinou P, Shoenfeld Y. Anti-pyruvate dehydrogenase autoantibodies in primary biliary cirrhosis. J Clin Immunol. 1991;11(5):239–45.PubMedCrossRef
199.
go back to reference Zurgil N, Bakimer R, Moutsopoulos HM, Tzioufas AG, Youinou P, Isenberg DA, et al. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol. 1992;12(3):201–9.PubMedCrossRef Zurgil N, Bakimer R, Moutsopoulos HM, Tzioufas AG, Youinou P, Isenberg DA, et al. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol. 1992;12(3):201–9.PubMedCrossRef
200.
go back to reference Zurgil N, Bakimer R, Slor H, Kaplan M, Moutsopoulos H, Shoenfeld Y. Pyruvate dehydrogenase as an antigen to detect antimitochondrial antibodies. Isr J Med Sci. 1990;26(12):682–5.PubMed Zurgil N, Bakimer R, Slor H, Kaplan M, Moutsopoulos H, Shoenfeld Y. Pyruvate dehydrogenase as an antigen to detect antimitochondrial antibodies. Isr J Med Sci. 1990;26(12):682–5.PubMed
201.
go back to reference Zurgil N, Konikoff F, Bakimer R, Slor H, Shoenfeld Y. Detection of antimitochondrial antibodies: characterization by enzyme immunoassay and immunoblotting. Autoimmunity. 1989;4(4):289–97.PubMedCrossRef Zurgil N, Konikoff F, Bakimer R, Slor H, Shoenfeld Y. Detection of antimitochondrial antibodies: characterization by enzyme immunoassay and immunoblotting. Autoimmunity. 1989;4(4):289–97.PubMedCrossRef
202.
go back to reference Tishler M, Alosachie I, Barka N, Lin HC, Gershwin ME, Peter JB, et al. Primary Sjogren’s syndrome and primary biliary cirrhosis: differences and similarities in the autoantibody profile. Clin Exp Rheumatol. 1995;13(4):497–500.PubMed Tishler M, Alosachie I, Barka N, Lin HC, Gershwin ME, Peter JB, et al. Primary Sjogren’s syndrome and primary biliary cirrhosis: differences and similarities in the autoantibody profile. Clin Exp Rheumatol. 1995;13(4):497–500.PubMed
203.
go back to reference Bean P, Sutphin MS, Liu Y, Anton R, Reynolds TB, Shoenfeld Y, et al. Carbohydrate-deficient transferrin and false-positive results for alcohol abuse in primary biliary cirrhosis: differential diagnosis by detection of mitochondrial autoantibodies. Clin Chem. 1995;41(6 Pt 1):858–61.PubMed Bean P, Sutphin MS, Liu Y, Anton R, Reynolds TB, Shoenfeld Y, et al. Carbohydrate-deficient transferrin and false-positive results for alcohol abuse in primary biliary cirrhosis: differential diagnosis by detection of mitochondrial autoantibodies. Clin Chem. 1995;41(6 Pt 1):858–61.PubMed
206.
go back to reference Dubel L, Tanaka A, Leung PS, Van de Water J, Coppel R, Roche T, et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology. 1999;29(4):1013–8. doi:10.1002/hep.510290403.PubMedCrossRef Dubel L, Tanaka A, Leung PS, Van de Water J, Coppel R, Roche T, et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology. 1999;29(4):1013–8. doi:10.​1002/​hep.​510290403.PubMedCrossRef
208.
go back to reference Palmer JM, Jones DE, Quinn J, McHugh A, Yeaman SJ. Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis. Hepatology. 1999;30(1):21–6. doi:10.1002/hep.510300106.PubMedCrossRef Palmer JM, Jones DE, Quinn J, McHugh A, Yeaman SJ. Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis. Hepatology. 1999;30(1):21–6. doi:10.​1002/​hep.​510300106.PubMedCrossRef
209.
go back to reference Van de Water J, Fregeau D, Davis P, Ansari A, Danner D, Leung P, et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol. 1988;141(7):2321–4.PubMed Van de Water J, Fregeau D, Davis P, Ansari A, Danner D, Leung P, et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol. 1988;141(7):2321–4.PubMed
210.
go back to reference Bogdanos DP, Liaskos C, Pares A, Norman G, Rigopoulou EI, Caballeria L et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology. 2007;45(6):1583; author reply -4. doi: 10.1002/hep.21678. Bogdanos DP, Liaskos C, Pares A, Norman G, Rigopoulou EI, Caballeria L et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology. 2007;45(6):1583; author reply -4. doi: 10.​1002/​hep.​21678.
211.
go back to reference Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol. 2001;34(3):366–72.PubMedCrossRef Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol. 2001;34(3):366–72.PubMedCrossRef
212.
go back to reference Miyachi K, Hankins RW, Matsushima H, Kikuchi F, Inomata T, Horigome T, et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun. 2003;20(3):247–54.PubMedCrossRef Miyachi K, Hankins RW, Matsushima H, Kikuchi F, Inomata T, Horigome T, et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun. 2003;20(3):247–54.PubMedCrossRef
213.
go back to reference Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45(1):118–27. doi:10.1002/hep.21472.PubMedCrossRef Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45(1):118–27. doi:10.​1002/​hep.​21472.PubMedCrossRef
214.
go back to reference Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005;54(4):528–32. doi:10.1136/gut.2003.036558.PubMedCrossRef Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005;54(4):528–32. doi:10.​1136/​gut.​2003.​036558.PubMedCrossRef
215.
go back to reference Itoh S, Ichida T, Yoshida T, Hayakawa A, Uchida M, Tashiro-Itoh T, et al. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 1998;13(3):257–65.PubMedCrossRef Itoh S, Ichida T, Yoshida T, Hayakawa A, Uchida M, Tashiro-Itoh T, et al. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 1998;13(3):257–65.PubMedCrossRef
216.
go back to reference Lassoued K, Guilly MN, Andre C, Paintrand M, Dhumeaux D, Danon F, et al. Autoantibodies to 200 kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis. Clin Exp Immunol. 1988;74(2):283–8.PubMed Lassoued K, Guilly MN, Andre C, Paintrand M, Dhumeaux D, Danon F, et al. Autoantibodies to 200 kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis. Clin Exp Immunol. 1988;74(2):283–8.PubMed
218.
go back to reference Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43(5):1135–44. doi:10.1002/hep.21172.PubMedCrossRef Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43(5):1135–44. doi:10.​1002/​hep.​21172.PubMedCrossRef
219.
go back to reference Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol. 2004;2(12):1116–22.PubMedCrossRef Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol. 2004;2(12):1116–22.PubMedCrossRef
222.
223.
go back to reference Floreani A, Naccarato R, Chiaramonte M. Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol. 1997;26(3):737–8.PubMedCrossRef Floreani A, Naccarato R, Chiaramonte M. Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol. 1997;26(3):737–8.PubMedCrossRef
225.
go back to reference Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology. 2007;46(3):785–92. doi:10.1002/hep.21749.PubMedCrossRef Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology. 2007;46(3):785–92. doi:10.​1002/​hep.​21749.PubMedCrossRef
226.
go back to reference Douglas JG, Finlayson ND. Are increased individual susceptibility and environmental factors both necessary for the development of primary biliary cirrhosis? BMJ. 1979;2(6187):419–20.PubMedCrossRef Douglas JG, Finlayson ND. Are increased individual susceptibility and environmental factors both necessary for the development of primary biliary cirrhosis? BMJ. 1979;2(6187):419–20.PubMedCrossRef
227.
go back to reference Fagan E, Williams R, Cox S. Primary biliary cirrhosis in mother and daughter. BMJ. 1977;2(6096):1195.PubMedCrossRef Fagan E, Williams R, Cox S. Primary biliary cirrhosis in mother and daughter. BMJ. 1977;2(6096):1195.PubMedCrossRef
228.
go back to reference Tong MJ, Nies KM, Reynolds TB, Quismorio FP. Immunological studies in familial primary biliary cirrhosis. Gastroenterology. 1976;71(2):305–7.PubMed Tong MJ, Nies KM, Reynolds TB, Quismorio FP. Immunological studies in familial primary biliary cirrhosis. Gastroenterology. 1976;71(2):305–7.PubMed
229.
go back to reference Smyk DS, Rigopoulou EI, Bogdanos DP. Potential roles for infectious agents in the pathophysiology of primary biliary cirrhosis: what’s new? Curr Infect Dis Rep. 2012;. doi:10.1007/s11908-012-0304-2. Smyk DS, Rigopoulou EI, Bogdanos DP. Potential roles for infectious agents in the pathophysiology of primary biliary cirrhosis: what’s new? Curr Infect Dis Rep. 2012;. doi:10.​1007/​s11908-012-0304-2.
232.
go back to reference Lleo A, Invernizzi P, Mackay IR, Prince H, Zhong RQ, Gershwin ME. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol. 2008;14(21):3328–37.PubMedCrossRef Lleo A, Invernizzi P, Mackay IR, Prince H, Zhong RQ, Gershwin ME. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol. 2008;14(21):3328–37.PubMedCrossRef
234.
go back to reference Wu SJ, Yang YH, Tsuneyama K, Leung PS, Illarionov P, Gershwin ME, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology. 2011;53(3):915–25. doi:10.1002/hep.24113.PubMedCrossRef Wu SJ, Yang YH, Tsuneyama K, Leung PS, Illarionov P, Gershwin ME, et al. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology. 2011;53(3):915–25. doi:10.​1002/​hep.​24113.PubMedCrossRef
235.
go back to reference Hirschfield GM, Gershwin ME. Primary biliary cirrhosis: one disease with many faces. Isr Med Assoc J. 2011;13(1):55–9.PubMed Hirschfield GM, Gershwin ME. Primary biliary cirrhosis: one disease with many faces. Isr Med Assoc J. 2011;13(1):55–9.PubMed
236.
238.
go back to reference Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):655–7. doi:10.1038/ng.631.PubMedCrossRef Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):655–7. doi:10.​1038/​ng.​631.PubMedCrossRef
240.
go back to reference Liu X, Invernizzi P, Lu Y, Kosoy R, Bianchi I, Podda M, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):658–60. doi:10.1038/ng.627.PubMedCrossRef Liu X, Invernizzi P, Lu Y, Kosoy R, Bianchi I, Podda M, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):658–60. doi:10.​1038/​ng.​627.PubMedCrossRef
241.
go back to reference Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011;43(4):329–32. doi:10.1038/ng.789.PubMedCrossRef Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011;43(4):329–32. doi:10.​1038/​ng.​789.PubMedCrossRef
243.
go back to reference Tanaka A, Ohira H, Kikuchi K, Nezu S, Shibuya A, Bianchi I, et al. Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. Tissue Antigens. 2011;77(3):239–43. doi:10.1111/j.1399-0039.2010.01600.x.PubMedCrossRef Tanaka A, Ohira H, Kikuchi K, Nezu S, Shibuya A, Bianchi I, et al. Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. Tissue Antigens. 2011;77(3):239–43. doi:10.​1111/​j.​1399-0039.​2010.​01600.​x.PubMedCrossRef
246.
go back to reference Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, Oertelt S, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology. 2007;46(2):456–62. doi:10.1002/hep.21696.PubMedCrossRef Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, Oertelt S, et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology. 2007;46(2):456–62. doi:10.​1002/​hep.​21696.PubMedCrossRef
247.
go back to reference Bogdanos DP, Baum H, Butler P, Rigopoulou EI, Davies ET, Ma Y, et al. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis. 2003;35(11):801–5.PubMedCrossRef Bogdanos DP, Baum H, Butler P, Rigopoulou EI, Davies ET, Ma Y, et al. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis. 2003;35(11):801–5.PubMedCrossRef
248.
go back to reference Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol. 2004;40(1):31–9.PubMedCrossRef Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol. 2004;40(1):31–9.PubMedCrossRef
250.
go back to reference Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology. 2005;42(2):458–65. doi:10.1002/hep.20788.PubMedCrossRef Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology. 2005;42(2):458–65. doi:10.​1002/​hep.​20788.PubMedCrossRef
251.
go back to reference Bogdanos DP, Baum H, Sharma UC, Grasso A, Ma Y, Burroughs AK, et al. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol. 2002;36(1):14–21.PubMedCrossRef Bogdanos DP, Baum H, Sharma UC, Grasso A, Ma Y, Burroughs AK, et al. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol. 2002;36(1):14–21.PubMedCrossRef
252.
go back to reference Fussey SP, Lindsay JG, Fuller C, Perham RN, Dale S, James OF, et al. Autoantibodies in primary biliary cirrhosis: analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes. Hepatology. 1991;13(3):467–74.PubMedCrossRef Fussey SP, Lindsay JG, Fuller C, Perham RN, Dale S, James OF, et al. Autoantibodies in primary biliary cirrhosis: analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes. Hepatology. 1991;13(3):467–74.PubMedCrossRef
253.
go back to reference Koutsoumpas A, Mytilinaiou M, Polymeros D, Dalekos GN, Bogdanos DP. Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies. Eur J Gastroenterol Hepatol. 2009;21(10):1220. doi:10.1097/MEG.0b013e32831a4807.PubMedCrossRef Koutsoumpas A, Mytilinaiou M, Polymeros D, Dalekos GN, Bogdanos DP. Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies. Eur J Gastroenterol Hepatol. 2009;21(10):1220. doi:10.​1097/​MEG.​0b013e32831a4807​.PubMedCrossRef
255.
go back to reference Burroughs AK, Butler P, Sternberg MJ, Baum H. Molecular mimicry in liver disease. Nature. 1992;358(6385):377–8.PubMedCrossRef Burroughs AK, Butler P, Sternberg MJ, Baum H. Molecular mimicry in liver disease. Nature. 1992;358(6385):377–8.PubMedCrossRef
256.
go back to reference Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut. 1984;25(2):133–7.PubMedCrossRef Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut. 1984;25(2):133–7.PubMedCrossRef
257.
go back to reference Butler P, Hamilton-Miller J, Baum H, Burroughs AK. Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis? Biochem Mol Biol Int. 1995;35(3):473–85.PubMed Butler P, Hamilton-Miller J, Baum H, Burroughs AK. Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis? Biochem Mol Biol Int. 1995;35(3):473–85.PubMed
258.
go back to reference Butler P, Hamilton-Miller JM, McIntyre N, Burroughs AK. Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups. Gut. 1995;36(6):931–4.PubMedCrossRef Butler P, Hamilton-Miller JM, McIntyre N, Burroughs AK. Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups. Gut. 1995;36(6):931–4.PubMedCrossRef
259.
go back to reference Butler P, Valle F, Hamilton-Miller JM, Brumfitt W, Baum H, Burroughs AK. M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol. 1993;17(3):408–14.PubMedCrossRef Butler P, Valle F, Hamilton-Miller JM, Brumfitt W, Baum H, Burroughs AK. M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol. 1993;17(3):408–14.PubMedCrossRef
260.
go back to reference Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut. 2004;53(4):599–608.PubMedCrossRef Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut. 2004;53(4):599–608.PubMedCrossRef
261.
go back to reference Floreani A, Bassendine MF, Mitchison H, Freeman R, James OF. No specific association between primary biliary cirrhosis and bacteriuria? J Hepatol. 1989;8(2):201–7.PubMedCrossRef Floreani A, Bassendine MF, Mitchison H, Freeman R, James OF. No specific association between primary biliary cirrhosis and bacteriuria? J Hepatol. 1989;8(2):201–7.PubMedCrossRef
262.
go back to reference Leung PS, Park O, Matsumura S, Ansari AA, Coppel RL, Gershwin ME. Is there a relation between Chlamydia infection and primary biliary cirrhosis? Clin Dev Immunol. 2003;10(2–4):227–33.PubMedCrossRef Leung PS, Park O, Matsumura S, Ansari AA, Coppel RL, Gershwin ME. Is there a relation between Chlamydia infection and primary biliary cirrhosis? Clin Dev Immunol. 2003;10(2–4):227–33.PubMedCrossRef
263.
go back to reference Mason A, Xu L, Shen Z, Fodera B, Joplin R, Neuberger J et al. Patients with primary biliary cirrhosis make anti-viral and anti-mitochondrial antibodies to mouse mammary tumor virus. Gastroenterology. 2004;127(6):1863-4; author reply 4-5. Mason A, Xu L, Shen Z, Fodera B, Joplin R, Neuberger J et al. Patients with primary biliary cirrhosis make anti-viral and anti-mitochondrial antibodies to mouse mammary tumor virus. Gastroenterology. 2004;127(6):1863-4; author reply 4-5.
264.
go back to reference McNally RJ, Ducker S, James OF. Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis. Hepatology. 2009;50(4):1169–74.PubMedCrossRef McNally RJ, Ducker S, James OF. Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis. Hepatology. 2009;50(4):1169–74.PubMedCrossRef
265.
go back to reference Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003;38(5):1250–7.PubMedCrossRef Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003;38(5):1250–7.PubMedCrossRef
266.
go back to reference Smyk D, Mytilinaiou MG, Rigopoulou EI, Bogdanos DP. PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Dis Markers. 2010;29(6):337–44. doi:10.3233/DMA-2010-0744.PubMedCrossRef Smyk D, Mytilinaiou MG, Rigopoulou EI, Bogdanos DP. PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. Dis Markers. 2010;29(6):337–44. doi:10.​3233/​DMA-2010-0744.PubMedCrossRef
267.
go back to reference Xu L, Sakalian M, Shen Z, Loss G, Neuberger J, Mason A. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology. 2004;39(1):151–6. doi:10.1002/hep.20024.PubMedCrossRef Xu L, Sakalian M, Shen Z, Loss G, Neuberger J, Mason A. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology. 2004;39(1):151–6. doi:10.​1002/​hep.​20024.PubMedCrossRef
268.
go back to reference Xu L, Shen Z, Guo L, Fodera B, Keogh A, Joplin R, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A. 2003;100(14):8454–9.PubMedCrossRef Xu L, Shen Z, Guo L, Fodera B, Keogh A, Joplin R, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A. 2003;100(14):8454–9.PubMedCrossRef
272.
go back to reference Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21(4):225–32.PubMedCrossRef Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21(4):225–32.PubMedCrossRef
274.
go back to reference Rigopoulou EI, Smyk DS, Matthews CE, Billinis C, Burroughs AK, Lenzi M, et al. Epstein-barr virus as a trigger of autoimmune liver diseases. Adv Virol. 2012;2012:987471. doi:10.1155/2012/987471.PubMed Rigopoulou EI, Smyk DS, Matthews CE, Billinis C, Burroughs AK, Lenzi M, et al. Epstein-barr virus as a trigger of autoimmune liver diseases. Adv Virol. 2012;2012:987471. doi:10.​1155/​2012/​987471.PubMed
275.
go back to reference Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6(3):727–37.PubMedCrossRef Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6(3):727–37.PubMedCrossRef
280.
282.
287.
289.
292.
go back to reference Bissonnette L, Bergeron MG. Multiparametric technologies for the diagnosis of syndromic infections. Clinical Microbiology Newsletter. 2012;34(20):159–68.CrossRef Bissonnette L, Bergeron MG. Multiparametric technologies for the diagnosis of syndromic infections. Clinical Microbiology Newsletter. 2012;34(20):159–68.CrossRef
294.
go back to reference Quintana FJ, Hagedorn PH, Elizur G, Merbl Y, Domany E, Cohen IR. Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14615–21. doi:10.1073/pnas.0404848101.PubMedCrossRef Quintana FJ, Hagedorn PH, Elizur G, Merbl Y, Domany E, Cohen IR. Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14615–21. doi:10.​1073/​pnas.​0404848101.PubMedCrossRef
297.
go back to reference O’Donohue J, Fidler H, Garcia-Barcelo M, Nouri-Aria K, Williams R, McFadden J. Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. J Hepatol. 1998;28(3):433–8.PubMedCrossRef O’Donohue J, Fidler H, Garcia-Barcelo M, Nouri-Aria K, Williams R, McFadden J. Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. J Hepatol. 1998;28(3):433–8.PubMedCrossRef
298.
go back to reference Tanaka A, Prindiville TP, Gish R, Solnick JV, Coppel RL, Keeffe EB, et al. Are infectious agents involved in primary biliary cirrhosis? A PCR approach. J Hepatol. 1999;31(4):664–71.PubMedCrossRef Tanaka A, Prindiville TP, Gish R, Solnick JV, Coppel RL, Keeffe EB, et al. Are infectious agents involved in primary biliary cirrhosis? A PCR approach. J Hepatol. 1999;31(4):664–71.PubMedCrossRef
299.
go back to reference Vilagut L, Pares A, Rodes J, Vila J, Vinas O, Gines A, et al. Mycobacteria–related to the aetiopathogenesis of primary biliary cirrhosis? J Hepatol. 1996;24(1):125.PubMedCrossRef Vilagut L, Pares A, Rodes J, Vila J, Vinas O, Gines A, et al. Mycobacteria–related to the aetiopathogenesis of primary biliary cirrhosis? J Hepatol. 1996;24(1):125.PubMedCrossRef
300.
go back to reference Chen EC, Miller SA, DeRisi JL, Chiu CY. Using a pan-viral microarray assay (Virochip) to screen clinical samples for viral pathogens. J Vis Exp. 2011;(50):e2536. doi:10.3791/2536. Chen EC, Miller SA, DeRisi JL, Chiu CY. Using a pan-viral microarray assay (Virochip) to screen clinical samples for viral pathogens. J Vis Exp. 2011;(50):e2536. doi:10.​3791/​2536.
301.
go back to reference Kistler A, Avila PC, Rouskin S, Wang D, Ward T, Yagi S, et al. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity. J Infect Dis. 2007;196(6):817–25. doi:10.1086/520816.PubMedCrossRef Kistler A, Avila PC, Rouskin S, Wang D, Ward T, Yagi S, et al. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity. J Infect Dis. 2007;196(6):817–25. doi:10.​1086/​520816.PubMedCrossRef
304.
305.
go back to reference Broome U, Scheynius A, Hultcrantz R. Induced expression of heat-shock protein on biliary epithelium in patients with primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology. 1993;18(2):298–303.PubMed Broome U, Scheynius A, Hultcrantz R. Induced expression of heat-shock protein on biliary epithelium in patients with primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology. 1993;18(2):298–303.PubMed
307.
go back to reference Ochoa-Reparaz J, Mielcarz DW, Ditrio LE, Burroughs AR, Foureau DM, Haque-Begum S, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol. 2009;183(10):6041–50. doi:10.4049/jimmunol.0900747.PubMedCrossRef Ochoa-Reparaz J, Mielcarz DW, Ditrio LE, Burroughs AR, Foureau DM, Haque-Begum S, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol. 2009;183(10):6041–50. doi:10.​4049/​jimmunol.​0900747.PubMedCrossRef
308.
go back to reference Helenius LM, Meurman JH, Helenius I, Kari K, Hietanen J, Suuronen R, et al. Oral and salivary parameters in patients with rheumatic diseases. Acta Odontol Scand. 2005;63(5):284–93.PubMedCrossRef Helenius LM, Meurman JH, Helenius I, Kari K, Hietanen J, Suuronen R, et al. Oral and salivary parameters in patients with rheumatic diseases. Acta Odontol Scand. 2005;63(5):284–93.PubMedCrossRef
310.
go back to reference Alvaro D, Alpini G, Onori P, Franchitto A, Glaser SS, Le Sage G, et al. Alfa and beta estrogen receptors and the biliary tree. Mol Cell Endocrinol. 2002;193(1–2):105–8.PubMedCrossRef Alvaro D, Alpini G, Onori P, Franchitto A, Glaser SS, Le Sage G, et al. Alfa and beta estrogen receptors and the biliary tree. Mol Cell Endocrinol. 2002;193(1–2):105–8.PubMedCrossRef
312.
go back to reference Duvic M, Steinberg AD, Klassen LW. Effect of the anti-estrogen, Nafoxidine, on NZB/W autoimmune disease. Arthritis Rheum. 1978;21(4):414–7.PubMedCrossRef Duvic M, Steinberg AD, Klassen LW. Effect of the anti-estrogen, Nafoxidine, on NZB/W autoimmune disease. Arthritis Rheum. 1978;21(4):414–7.PubMedCrossRef
313.
go back to reference Holmdahl R. Estrogen exaggerates lupus but suppresses T-cell-dependent autoimmune disease. J Autoimmun. 1989;2(5):651–6.PubMedCrossRef Holmdahl R. Estrogen exaggerates lupus but suppresses T-cell-dependent autoimmune disease. J Autoimmun. 1989;2(5):651–6.PubMedCrossRef
315.
go back to reference Mizutani T, Shinoda M, Tanaka Y, Kuno T, Hattori A, Usui T, et al. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab Rev. 2005;37(1):235–52. doi:10.1081/DMR-200028798.PubMed Mizutani T, Shinoda M, Tanaka Y, Kuno T, Hattori A, Usui T, et al. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab Rev. 2005;37(1):235–52. doi:10.​1081/​DMR-200028798.PubMed
316.
go back to reference Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol. 2000;32(1 Suppl):181–97.PubMedCrossRef Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol. 2000;32(1 Suppl):181–97.PubMedCrossRef
318.
go back to reference Khokhar O, Gange C, Clement S, Lewis J. Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction. Dig Dis Sci. 2005;50(1):207–11.PubMedCrossRef Khokhar O, Gange C, Clement S, Lewis J. Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction. Dig Dis Sci. 2005;50(1):207–11.PubMedCrossRef
320.
go back to reference Ahrens N, Genth R, Salama A. Belated diagnosis in three patients with rifampicin-induced immune haemolytic anaemia. Br J Haematol. 2002;117(2):441–3.PubMedCrossRef Ahrens N, Genth R, Salama A. Belated diagnosis in three patients with rifampicin-induced immune haemolytic anaemia. Br J Haematol. 2002;117(2):441–3.PubMedCrossRef
321.
go back to reference Heurgue-Berlot A, Bernard-Chabert B, Diebold MD, Thiefin G. Drug-induced autoimmune-like hepatitis: a case of chronic course after drug withdrawal. Dig Dis Sci. 2011;56(8):2504-5; author reply 5. doi:10.1007/s10620-011-1786-8. Heurgue-Berlot A, Bernard-Chabert B, Diebold MD, Thiefin G. Drug-induced autoimmune-like hepatitis: a case of chronic course after drug withdrawal. Dig Dis Sci. 2011;56(8):2504-5; author reply 5. doi:10.​1007/​s10620-011-1786-8.
322.
go back to reference Bjornsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–8. doi:10.1002/hep.23588.PubMedCrossRef Bjornsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–8. doi:10.​1002/​hep.​23588.PubMedCrossRef
324.
go back to reference Angulo JM, Sigal LH, Espinoza LR. Minocycline induced lupus and autoimmune hepatitis. J Rheumatol. 1999;26(6):1420–1.PubMed Angulo JM, Sigal LH, Espinoza LR. Minocycline induced lupus and autoimmune hepatitis. J Rheumatol. 1999;26(6):1420–1.PubMed
325.
go back to reference Bachmeyer C, Cadranel JF. Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors. Dermatology. 2002;205(2):185–6.PubMedCrossRef Bachmeyer C, Cadranel JF. Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors. Dermatology. 2002;205(2):185–6.PubMedCrossRef
326.
go back to reference Bhat G, Jordan J Jr, Sokalski S, Bajaj V, Marshall R, Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol. 1998;27(1):74–5.PubMedCrossRef Bhat G, Jordan J Jr, Sokalski S, Bajaj V, Marshall R, Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol. 1998;27(1):74–5.PubMedCrossRef
328.
go back to reference Colmegna I, Perandones CE, Chaves JG. Minocycline induced lupus and autoimmune hepatitis. J Rheumatol. 2000;27(6):1567–8.PubMed Colmegna I, Perandones CE, Chaves JG. Minocycline induced lupus and autoimmune hepatitis. J Rheumatol. 2000;27(6):1567–8.PubMed
329.
go back to reference Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312(7024):169–72.PubMedCrossRef Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312(7024):169–72.PubMedCrossRef
332.
go back to reference Karali Z, Basaranoglu ST, Karali Y, Oral B, Kilic SS. Autoimmunity and hepatitis A vaccine in children. J Investig Allergol Clin Immunol. 2011;21(5):389–93.PubMed Karali Z, Basaranoglu ST, Karali Y, Oral B, Kilic SS. Autoimmunity and hepatitis A vaccine in children. J Investig Allergol Clin Immunol. 2011;21(5):389–93.PubMed
335.
go back to reference Aron-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus. 2001;10(3):237–40.PubMedCrossRef Aron-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus. 2001;10(3):237–40.PubMedCrossRef
336.
go back to reference Borchers AT, Keen CL, Shoenfeld Y, Silva J Jr, Gershwin ME. Vaccines, viruses, and voodoo. J Investig Allergol Clin Immunol. 2002;12(3):155–68.PubMed Borchers AT, Keen CL, Shoenfeld Y, Silva J Jr, Gershwin ME. Vaccines, viruses, and voodoo. J Investig Allergol Clin Immunol. 2002;12(3):155–68.PubMed
339.
341.
go back to reference Shoenfeld Y, Aharon-Maor A, Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol. 2000;18(2):181–4.PubMed Shoenfeld Y, Aharon-Maor A, Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol. 2000;18(2):181–4.PubMed
344.
go back to reference Costenbader KH, Gay S, Riquelme ME, Iaccarino L, Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev. 2011;. doi:10.1016/j.autrev.2011.10.022. Costenbader KH, Gay S, Riquelme ME, Iaccarino L, Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev. 2011;. doi:10.​1016/​j.​autrev.​2011.​10.​022.
348.
go back to reference Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006;15(11):737–45.PubMedCrossRef Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006;15(11):737–45.PubMedCrossRef
349.
go back to reference Rubin RL, Hermanson TM, Bedrick EJ, McDonald JD, Burchiel SW, Reed MD, et al. Effect of cigarette smoke on autoimmunity in murine and human systemic lupus erythematosus. Toxicol Sci. 2005;87(1):86–96. doi:10.1093/toxsci/kfi217.PubMedCrossRef Rubin RL, Hermanson TM, Bedrick EJ, McDonald JD, Burchiel SW, Reed MD, et al. Effect of cigarette smoke on autoimmunity in murine and human systemic lupus erythematosus. Toxicol Sci. 2005;87(1):86–96. doi:10.​1093/​toxsci/​kfi217.PubMedCrossRef
350.
go back to reference Asherson RA, Shoenfeld Y, Jacobs P, Bosman C. An unusually complicated case of primary Sjogren’s syndrome: development of transient “lupus-type” autoantibodies following silicone implant rejection. J Rheumatol. 2004;31(1):196–7.PubMed Asherson RA, Shoenfeld Y, Jacobs P, Bosman C. An unusually complicated case of primary Sjogren’s syndrome: development of transient “lupus-type” autoantibodies following silicone implant rejection. J Rheumatol. 2004;31(1):196–7.PubMed
351.
go back to reference Bar-Meir E, Eherenfeld M, Shoenfeld Y. Silicone gel breast implants and connective tissue disease–a comprehensive review. Autoimmunity. 2003;36(4):193–7.PubMedCrossRef Bar-Meir E, Eherenfeld M, Shoenfeld Y. Silicone gel breast implants and connective tissue disease–a comprehensive review. Autoimmunity. 2003;36(4):193–7.PubMedCrossRef
352.
go back to reference Bar-Meir E, Teuber SS, Lin HC, Alosacie I, Goddard G, Terybery J, et al. Multiple autoantibodies in patients with silicone breast implants. J Autoimmun. 1995;8(2):267–77.PubMedCrossRef Bar-Meir E, Teuber SS, Lin HC, Alosacie I, Goddard G, Terybery J, et al. Multiple autoantibodies in patients with silicone breast implants. J Autoimmun. 1995;8(2):267–77.PubMedCrossRef
353.
go back to reference Vasey FB, Zarabadi SA, Seleznick M, Ricca L. Where there’s smoke there’s fire: the silicone breast implant controversy continues to flicker: a new disease that needs to be defined. J Rheumatol. 2003;30(10):2092–4.PubMed Vasey FB, Zarabadi SA, Seleznick M, Ricca L. Where there’s smoke there’s fire: the silicone breast implant controversy continues to flicker: a new disease that needs to be defined. J Rheumatol. 2003;30(10):2092–4.PubMed
354.
go back to reference Vermeulen RC, Scholte HR. Rupture of silicone gel breast implants and symptoms of pain and fatigue. J Rheumatol. 2003;30(10):2263–7.PubMed Vermeulen RC, Scholte HR. Rupture of silicone gel breast implants and symptoms of pain and fatigue. J Rheumatol. 2003;30(10):2263–7.PubMed
355.
go back to reference Zandman-Goddard G, Blank M, Ehrenfeld M, Gilburd B, Peter J, Shoenfeld Y. A comparison of autoantibody production in asymptomatic and symptomatic women with silicone breast implants. J Rheumatol. 1999;26(1):73–7.PubMed Zandman-Goddard G, Blank M, Ehrenfeld M, Gilburd B, Peter J, Shoenfeld Y. A comparison of autoantibody production in asymptomatic and symptomatic women with silicone breast implants. J Rheumatol. 1999;26(1):73–7.PubMed
358.
360.
go back to reference Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol. 2010;67(6):824–30. doi:10.1002/ana.21978.PubMed Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol. 2010;67(6):824–30. doi:10.​1002/​ana.​21978.PubMed
361.
go back to reference Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA. 2005;293(20):2496–500. doi:10.1001/jama.293.20.2496.PubMedCrossRef Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA. 2005;293(20):2496–500. doi:10.​1001/​jama.​293.​20.​2496.PubMedCrossRef
362.
go back to reference Lindberg C, Andersen O, Vahlne A, Dalton M, Runmarker B. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology. 1991;10(2):62–5.PubMedCrossRef Lindberg C, Andersen O, Vahlne A, Dalton M, Runmarker B. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology. 1991;10(2):62–5.PubMedCrossRef
363.
go back to reference Lunemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Munz C, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain. 2006;129(Pt 6):1493–506. doi:10.1093/brain/awl067.PubMedCrossRef Lunemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Munz C, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain. 2006;129(Pt 6):1493–506. doi:10.​1093/​brain/​awl067.PubMedCrossRef
365.
go back to reference Lunemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med. 2008;205(8):1763–73. doi:10.1084/jem.20072397.PubMedCrossRef Lunemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med. 2008;205(8):1763–73. doi:10.​1084/​jem.​20072397.PubMedCrossRef
366.
go back to reference Operskalski EA, Visscher BR, Malmgren RM, Detels R. A case-control study of multiple sclerosis. Neurology. 1989;39(6):825–9.PubMedCrossRef Operskalski EA, Visscher BR, Malmgren RM, Detels R. A case-control study of multiple sclerosis. Neurology. 1989;39(6):825–9.PubMedCrossRef
367.
go back to reference Peferoen LA, Lamers F, Lodder LN, Gerritsen WH, Huitinga I, Melief J, et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain. 2010;133(Pt 5):e137. doi:10.1093/brain/awp296.PubMedCrossRef Peferoen LA, Lamers F, Lodder LN, Gerritsen WH, Huitinga I, Melief J, et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain. 2010;133(Pt 5):e137. doi:10.​1093/​brain/​awp296.PubMedCrossRef
369.
go back to reference Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12):2899–912. doi:10.1084/jem.20071030.PubMedCrossRef Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12):2899–912. doi:10.​1084/​jem.​20071030.PubMedCrossRef
371.
372.
go back to reference Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132(Pt 12):3318–28. doi:10.1093/brain/awp200.PubMedCrossRef Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132(Pt 12):3318–28. doi:10.​1093/​brain/​awp200.PubMedCrossRef
373.
go back to reference Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol. 1999;46(1):6–14.PubMedCrossRef Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol. 1999;46(1):6–14.PubMedCrossRef
374.
go back to reference Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A. 1995;92(16):7440–4.PubMedCrossRef Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A. 1995;92(16):7440–4.PubMedCrossRef
375.
376.
go back to reference Chmielewska-Badora J, Cisak E, Dutkiewicz J. Lyme borreliosis and multiple sclerosis: any connection? A seroepidemic study. Ann Agric Environ Med. 2000;7(2):141–3.PubMed Chmielewska-Badora J, Cisak E, Dutkiewicz J. Lyme borreliosis and multiple sclerosis: any connection? A seroepidemic study. Ann Agric Environ Med. 2000;7(2):141–3.PubMed
377.
go back to reference Mancuso R, Delbue S, Borghi E, Pagani E, Calvo MG, Caputo D, et al. Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis. J Med Virol. 2007;79(2):192–9. doi:10.1002/jmv.20777.PubMedCrossRef Mancuso R, Delbue S, Borghi E, Pagani E, Calvo MG, Caputo D, et al. Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis. J Med Virol. 2007;79(2):192–9. doi:10.​1002/​jmv.​20777.PubMedCrossRef
381.
go back to reference Wroblewska Z, Gilden D, Devlin M, Huang ES, Rorke LB, Hamada T, et al. Cytomegalovirus isolation from a chimpanzee with acute demyelinating disease after inoculation of multiple sclerosis brain cells. Infect Immun. 1979;25(3):1008–15.PubMed Wroblewska Z, Gilden D, Devlin M, Huang ES, Rorke LB, Hamada T, et al. Cytomegalovirus isolation from a chimpanzee with acute demyelinating disease after inoculation of multiple sclerosis brain cells. Infect Immun. 1979;25(3):1008–15.PubMed
382.
go back to reference Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-Pradel F, et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. the collaborative research group on multiple sclerosis. Proc Natl Acad Sci U S A. 1997;94(14):7583–8.PubMedCrossRef Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-Pradel F, et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. the collaborative research group on multiple sclerosis. Proc Natl Acad Sci U S A. 1997;94(14):7583–8.PubMedCrossRef
383.
go back to reference Rasmussen HB, Geny C, Deforges L, Perron H, Tourtelotte W, Heltberg A, et al. Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients. Acta Neurol Scand Supplementum. 1997;169:38–44.CrossRef Rasmussen HB, Geny C, Deforges L, Perron H, Tourtelotte W, Heltberg A, et al. Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients. Acta Neurol Scand Supplementum. 1997;169:38–44.CrossRef
385.
go back to reference Stewart JN, Mounir S, Talbot PJ. Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology. 1992;191(1):502–5.PubMedCrossRef Stewart JN, Mounir S, Talbot PJ. Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology. 1992;191(1):502–5.PubMedCrossRef
386.
go back to reference Ferrante P, Omodeo-Zorini E, Caldarelli-Stefano R, Mediati M, Fainardi E, Granieri E, et al. Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients. Mult Scler. 1998;4(2):49–54.PubMed Ferrante P, Omodeo-Zorini E, Caldarelli-Stefano R, Mediati M, Fainardi E, Granieri E, et al. Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients. Mult Scler. 1998;4(2):49–54.PubMed
387.
go back to reference Stoner GL, Agostini HT, Ryschkewitsch CF, Baumhefner RW, Tourtellotte WW. Characterization of JC virus DNA amplified from urine of chronic progressive multiple sclerosis patients. Mult Scler. 1996;1(4):193–9.PubMed Stoner GL, Agostini HT, Ryschkewitsch CF, Baumhefner RW, Tourtellotte WW. Characterization of JC virus DNA amplified from urine of chronic progressive multiple sclerosis patients. Mult Scler. 1996;1(4):193–9.PubMed
388.
go back to reference Forghani B, Cremer NE, Johnson KP, Ginsberg AH, Likosky WH. Viral antibodies in cerebrospinal fluid of multiple sclerosis and control patients: comparison between radioimmunoassay and conventional techniques. J Clin Microbiol. 1978;7(1):63–9.PubMed Forghani B, Cremer NE, Johnson KP, Ginsberg AH, Likosky WH. Viral antibodies in cerebrospinal fluid of multiple sclerosis and control patients: comparison between radioimmunoassay and conventional techniques. J Clin Microbiol. 1978;7(1):63–9.PubMed
389.
go back to reference ter Meulen V, Koprowski H, Iwasaki Y, Kackell YM, Muller D. Fusion of cultured multiple-sclerosis brain cells with indicator cells: presence of nucleocapsids and virions and isolation of parainfluenza-type virus. Lancet. 1972;2(7766):1–5.PubMedCrossRef ter Meulen V, Koprowski H, Iwasaki Y, Kackell YM, Muller D. Fusion of cultured multiple-sclerosis brain cells with indicator cells: presence of nucleocapsids and virions and isolation of parainfluenza-type virus. Lancet. 1972;2(7766):1–5.PubMedCrossRef
390.
go back to reference Haase AT, Ventura P, Gibbs CJ Jr, Tourtellotte WW. Measles virus nucleotide sequences: detection by hybridization in situ. Science. 1981;212(4495):672–5.PubMedCrossRef Haase AT, Ventura P, Gibbs CJ Jr, Tourtellotte WW. Measles virus nucleotide sequences: detection by hybridization in situ. Science. 1981;212(4495):672–5.PubMedCrossRef
391.
go back to reference Jacobson S, Flerlage ML, McFarland HF. Impaired measles virus-specific cytotoxic T cell responses in multiple sclerosis. J Exp Med. 1985;162(3):839–50.PubMedCrossRef Jacobson S, Flerlage ML, McFarland HF. Impaired measles virus-specific cytotoxic T cell responses in multiple sclerosis. J Exp Med. 1985;162(3):839–50.PubMedCrossRef
392.
go back to reference Alpérovitch A, Berr C, Cambon-Thomsen A, Puel J, Dugoujon JM, Ruidavets JB, et al. Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls. Hum Immunol. 1991;31(2):94–9. doi:10.1016/0198-8859(91)90011-W.PubMedCrossRef Alpérovitch A, Berr C, Cambon-Thomsen A, Puel J, Dugoujon JM, Ruidavets JB, et al. Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls. Hum Immunol. 1991;31(2):94–9. doi:10.​1016/​0198-8859(91)90011-W.PubMedCrossRef
394.
go back to reference Shigematsu H, Shimoda S, Nakamura M, Matsushita S, Nishimura Y, Sakamoto N, et al. Fine specificity of T cells reactive to human PDC-E2 163–176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. Hepatology. 2000;32(5):901–9. doi:10.1053/jhep.2000.18714.PubMedCrossRef Shigematsu H, Shimoda S, Nakamura M, Matsushita S, Nishimura Y, Sakamoto N, et al. Fine specificity of T cells reactive to human PDC-E2 163–176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. Hepatology. 2000;32(5):901–9. doi:10.​1053/​jhep.​2000.​18714.PubMedCrossRef
395.
go back to reference Bogdanos DP, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun. 2004;22(4):353–62. doi:10.1016/j.jaut.2004.03.002.PubMedCrossRef Bogdanos DP, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun. 2004;22(4):353–62. doi:10.​1016/​j.​jaut.​2004.​03.​002.PubMedCrossRef
396.
go back to reference Vilagut L, Pares A, Vinas O, Vila J, Jimenez de Anta MT, Rodes J. Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis. Eur J Clin Invest. 1997;27(8):667–72.PubMedCrossRef Vilagut L, Pares A, Vinas O, Vila J, Jimenez de Anta MT, Rodes J. Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis. Eur J Clin Invest. 1997;27(8):667–72.PubMedCrossRef
397.
go back to reference Vilagut L, Vila J, Vinas O, Pares A, Gines A, Jimenez de Anta MT, et al. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol. 1994;21(4):673–7.PubMedCrossRef Vilagut L, Vila J, Vinas O, Pares A, Gines A, Jimenez de Anta MT, et al. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol. 1994;21(4):673–7.PubMedCrossRef
Metadata
Title
Tracing environmental markers of autoimmunity: introducing the infectome
Authors
Dimitrios P. Bogdanos
Daniel S. Smyk
Pietro Invernizzi
Eirini I. Rigopoulou
Miri Blank
Lazaros Sakkas
Shideh Pouria
Yehuda Shoenfeld
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Immunologic Research / Issue 2-3/2013
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-013-8399-6

Other articles of this Issue 2-3/2013

Immunologic Research 2-3/2013 Go to the issue

Diagnosis of Autoimmunity

Complement and autoimmunity